Description

3-[2-[4-(4-Fluorobenzoyl)Piperidino]Ethyl]-2,3-Dihydro-2-Thioxoquinazolin-4(1H)-One [R-(R*,R*)]-Tartrate is a high-purity, stereochemically defined pharmaceutical intermediate. This compound is critical for research and development in the synthesis of novel therapeutic agents, offering a precise building block for complex molecular architectures. It is primarily required by pharmaceutical R&D laboratories and fine chemical manufacturers focused on developing new drug candidates, particularly in the central nervous system and metabolic disorder therapeutic areas.

Application

• Pharmaceutical Intermediate: Key building block in the research and synthesis of proprietary drug candidates.
• Chemical Reference Standard: Used as a high-purity standard for analytical method development and validation in QC laboratories.
• Medicinal Chemistry Research: Serves as a core scaffold for structure-activity relationship (SAR) studies and lead optimization.
• Process Chemistry Development: Employed in route scouting and scale-up studies for active pharmaceutical ingredient (API) manufacturing.
• Academic Research: Utilized in university and institutional labs for pharmacological and biochemical studies.
• Contract Research & Manufacturing (CRO/CMO): Supplied to organizations providing custom synthesis and development services.

Basic Information

Product Name	3-[2-[4-(4-Fluorobenzoyl)Piperidino]Ethyl]-2,3-Dihydro-2-Thioxoquinazolin-4(1H)-One [R-(R*,R*)]-Tartrate
CAS No.	79449-96-0
Molecular Formula	C30H31FN4O7S
Molecular Weight	602.65 g/mol
Synonyms	(R,R)-Tartrate salt of 3-[2-[4-(4-Fluorobenzoyl)piperidino]ethyl]-2-thioxo-2,3-dihydro-4(1H)-quinazolinone; 79449-96-0; (2R,3R)-2,3-Dihydroxysuccinic acid - 3-[2-[4-(4-fluorobenzoyl)piperidino]ethyl]-2-sulfanylidene-1H-quinazolin-4-one (1:1); UNII-9F6Q4S8P4R; 9F6Q4S8P4R; CCG-40236; 3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
EINECS	Contact for details

Quality Control

Our 3-[2-[4-(4-Fluorobenzoyl)Piperidino]Ethyl]-2,3-Dihydro-2-Thioxoquinazolin-4(1H)-One [R-(R*,R*)]-Tartrate is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including chiral purity verification by HPLC, to ensure it meets the stringent requirements for pharmaceutical development. Certificates of Analysis (COA) with detailed chromatographic and spectroscopic data are provided and can be tailored to support regulatory filings.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15°C and 25°C (59°F and 77°F), in a dry environment. The container should be kept tightly sealed to protect the contents from moisture.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity (HPLC)	≥ 99.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 1.0%; Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.